

## NOTIFICATION AND FORM FOR ADVANCE VOTING

by postal voting in accordance with section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of shareholders' meetings in companies and other associations.

**To be received by Ascelia Pharma AB no later than Monday 12 April 2021.**

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in Ascelia Pharma AB, Reg. No. 556571-8797, at the extraordinary general meeting on Tuesday 13 April 2021. The voting right is exercised in accordance with the voting options marked in Schedule 1 below.

Name of the shareholder:	Personal identification number or corporate registration number:
--------------------------	--

**Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity):** I, the undersigned, am a board member, CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

**Assurance (if the undersigned represents the shareholder by proxy):** I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Place and date:	
Signature:	
Clarification of signature:	
Telephone number:	E-mail:

If issued by a legal entity, the form must be signed by authorized representative(s) and be accompanied by a registration certificate or, concerning foreign legal entities, corresponding documents evidencing the authorized representative(s) of the shareholder. The same applies if the shareholder votes in advance through a proxy.

The form, and a copy of the registration certificate or corresponding documents (if applicable) shall be sent to Ascelia Pharma AB, Att. Kristian Borbos, Hyllie Boulevard 34, SE-215 32 Malmö, Sweden, or via e-mail to: [kb@ascelia.com](mailto:kb@ascelia.com). The completed form must be submitted to Ascelia Pharma AB no later than on Monday 12 April 2021.

In Schedule 1, the votes shall be set forth. A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. Only one form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The latest form received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. For complete proposals for resolutions, please refer to the notice of the meeting and the complete proposals, available on the company's website ([www.ascelia.com](http://www.ascelia.com)).

Should you have any questions, please contact Ascelia Pharma AB via e-mail address [kb@ascelia.com](mailto:kb@ascelia.com) or phone number +46 735 17 91 13. For information on how your personal data is processed, see <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.

Please note that submitting this form will be regarded as giving notice of your attendance at the meeting. Please note that a prerequisite for an advance vote to be taken into account is that the shareholder who has cast the vote is registered in his/her own name in the share register kept by Euroclear Sweden AB prior to the meeting. Further instructions on this can be found in the notice to the meeting.

This form for advance voting may be revoked by written notice to Ascelia Pharma AB on the address above or via e-mail to [kb@ascelia.com](mailto:kb@ascelia.com), no later than Monday 12 April 2021.

*Schedule 1 follow on the next page*

**Schedule 1 – Voting form for advance voting at extraordinary general meeting in Ascelia Pharma AB on 13 April 2021**

The voting alternatives below refer, unless otherwise stated in the form, to the proposals stated in the notice to the meeting.

<b>1. Election of chairman of the meeting</b>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<b>2. Preparation and approval of the voting list</b>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<b>3. Approval of the agenda</b>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<b>4. Election of one or two persons who shall approve the minutes of the meeting</b>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<b>5. Determination of whether the meeting was duly convened</b>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<b>6. Resolution on approval of the board of directors' resolution on directed issue of shares</b>	Yes <input type="checkbox"/>	No <input type="checkbox"/>

**The shareholder wishes that resolution(s) under one or several items in the form shall be deferred to a continued shareholders' meeting**  
(completed only if the shareholder has such a wish)

**List item or items (use numbers):**

---